Patient-reported outcome (PRO) results from the AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum-resistant ovarian cancer (PROC)

被引：0
|
作者：
Hilbert, F. [1 ]
Gropp-Meier, M. [2 ]
Schmalfeldt, B. [2 ]
Rau, J. [3 ]
Meier, W. [4 ]
Hasenburg, A. [5 ]
Belau, A. [6 ]
Vergote, I. [7 ]
Zorr, A. [8 ]
Hils, R. [9 ]
Gerber, B. [10 ]
du Bois, A. [11 ]
Marme, F. [12 ]
Mahner, S. [13 ]
Canzler, U. [14 ]
Lueck, H. -J. [15 ]
Grischke, E. -M [16 ]
Kurzeder, C. [11 ]
机构：
[1] UKSH Campus Kiel, Klin Gynakol & Geburtshilfe, Kiel, Germany
[2] Gynakol Onkol & Brustzentrum, Oberschwabenklin, Ravensburg, Germany
[3] Univ Marburg, KKS, Marburg, Germany
[4] Evangel Krankenhaus, Frauenklin, Dusseldorf, Germany
[5] Univ Klin, Frauenklin, Freiburg, Germany
[6] Ernst Moritz Arndt Univ Greifswald, Univ Klinikum Greifswald, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Greifswald, Germany
[7] Univ Hosp, Gynecol Oncol, Leuven, Belgium
[8] Klinikum Konstanz, Frauenklin, Constance, Germany
[9] HSK, Gynakol & Gynakol Onkol, Wiesbaden, Germany
[10] Klinikum Sudstadt, Univ Frauenklin & Poliklin, Rostock, Germany
[11] Kliniken Essen Mitte, Klin Gynakol Onkol, Essen, Germany
[12] Univ Frauenklin, Natl Ctr Tumorerkrankungen, Heidelberg, Germany
[13] Klinikum Univ Munchen, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany
[14] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Dresden, Germany
[15] Gynakol Onkol Praxis Pelikanpl, Hannover, Germany
[16] Univ Klinikum Tubingen, Univ Frauenklin, Tubingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0087
引用
收藏
页码：138 / 138
页数：1
相关论文
共 46 条
  • [31] Primary Results From IMagyn050/GOG 3015/ENGOT-OV39, a Double-Blind Placebo-Controlled Randomized Phase 3 Trial of Bevacizumab-Containing Therapy +/- Atezolizumab for Newly Diagnosed Stage III/IV Ovarian Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (11) : 12 - 13
  • [32] Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lisyanskaya, Alla
    Kim, Jae-Hoon
    Filho, Elias Abdo
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Rowe, Phil
    Vergote, Ignace
    Pujade-Lauraine, Eric
    LANCET ONCOLOGY, 2021, 22 (05): : 620 - 631
  • [33] Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lisyanskaya, Alla
    Kim, Jae-Hoon
    Filho, Elias Abdo
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Rowe, Phil
    Vergote, Ignace
    Pujade-Lauraine, Eric
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2021, 76 (09) : 535 - 536
  • [34] Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy plus /- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
    Moore, K. N.
    Bookman, M.
    Sehouli, J.
    Miller, A.
    Anderson, C.
    Scambia, G.
    Myers, T.
    Taskiran, C.
    Robison, K.
    Maenpaa, J.
    Willmott, L. J.
    Colombo, N.
    Thomes-Pepin, J.
    Gold, M. A.
    Aghajanian, C.
    Wu, F.
    Molinero, L.
    Khor, V.
    Lin, Y. G.
    Pignata, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1161 - S1162
  • [35] AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer
    Fuh, Katherine Cynthia
    Tsitsishvili, Zaza
    Reid, Thomas J.
    De Giorgi, Ugo
    Hand, Lauren
    Bowen, Rebecca
    Miller, Devin
    Vulsteke, Christof
    Sharma, Sudarshan K.
    Chudecka-Glaz, Anita M.
    Liu, Joyce F.
    Eberst, Lauriane
    Neff, Robert
    Lim, Peter C.
    Iglesias, David A.
    Jenkins Vogel, Tilley
    Myers, Tashanna K. N.
    Gonzalez-Martin, Antonio
    Gonzalez Martin, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA5515 - LBA5515
  • [36] ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib 1 the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
    Fujiwara, K.
    Chou, H-H.
    Kim, J-W.
    Tan, D. S.
    Tamura, K.
    Katsumata, N.
    Harano, K.
    Hasegawa, K.
    Hume, S.
    Jones, E.
    Goble, S.
    Sullivan, L.
    Shih, D.
    Coleman, R. L.
    McNeish, I.
    Monk, B.
    Kristeleit, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
    Novello, Silvia
    Kaiser, Rolf
    Mellemgaard, Anders
    Douillard, Jean-Yves
    Orlov, Sergey
    Krzakowski, Maciej
    von Pawel, Joachim
    Gottfried, Maya
    Bondarenko, Igor
    Liao, Meilin
    Barrueco, Jose
    Gaschler-Markefski, Birgit
    Griebsch, Ingolf
    Palmer, Michael
    Reck, Martin
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (03) : 317 - 326
  • [38] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial (vol 18, pg 1274, 2017)
    Pujade-Lauraine, E.
    Ledermann, J. A.
    Selle, F.
    LANCET ONCOLOGY, 2017, 18 (09): : E510 - E510
  • [39] Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
    Oliveira, Mafalda
    Rugo, Hope S.
    Howell, Sacha J.
    Dalenc, Florence
    Cortes, Javier
    Gomez, Henry L.
    Hu, Xichun
    Toi, Masakazu
    Jhaveri, Komal
    Krivorotko, Petr
    Loibl, Sibylle
    Murillo, Serafin Morales
    Okera, Meena
    Nowecki, Zbigniew
    Park, Yeon Hee
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Yousef, Samih
    Zhukova, Lyudmila
    Fulford, Marta
    Andrews, Haylee
    Wadsworth, Ian
    D'Cruz, Celina
    Turner, Nicholas C.
    LANCET ONCOLOGY, 2024, 25 (09): : 1231 - 1244
  • [40] Improvement in patient-reported hair loss outcome measures in patients with alopecia areata treated with ritlecitinib: 48-week results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
    Sinclair, Rodney
    Mesinkovska, Natasha
    Mitra, Debanjali
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB69 - AB69
12345